EP4066856

PEGYLATED LIPOSOMES FOR DELIVERY OF IMMUNOGEN-ENCODING RNA

granted
JurisdiktionEP
Anmeldedatum31. Aug. 2011
Veröffentlichungsdatum07. Dez. 2022
Erteilungsdatum07. Dez. 2022
Ablaufdatum31. Aug. 2031
Veröffentlichungsnr.EP4066856
Anmeldenr.EP22174931
UPC-Verfahren5

Zusammenfassung

[0001] Nucleic acid immunisation is achieved by delivering RNA encapsulated within a PEGylated liposome. The RNA encodes an immunogen of interest. The PEG has an average molecular mass of between 1kDa and 3kDa. Thus the invention provides a liposome having a lipid bilayer encapsulating an aqueous core, wherein: (i) the lipid bilayer comprises at least one lipid which includes a polyethylene glycol moiety, such that polyethylene glycol is present on the liposome's exterior, wherein the average molecular mass of the polyethylene glycol is between 1kDa and 3kDa; and (ii) the aqueous core includes a RNA which encodes an immunogen. These liposomes are suitable for in vivo delivery of the RNA to a vertebrate cell and so they are useful as components in pharmaceutical compositions for immunising subjects against various diseases.

Anmelder

GLAXOSMITHKLINE BIOLOGICALS SA [BE]

Erfinder

GEALL ANDREW [US]VERMA AYUSH [US]

Externe Quellen

Klassifikation

IPC-Klassen
A61K 39/39A61K 9/127
CPC-Klassen
A61K 39/12A61K 39/155A61K 39/39A61K 9/0019A61K 9/10A61K 9/127A61K 9/1271A61P 31/00A61P 31/10A61P 31/12A61P 33/00A61P 37/04C12N 15/88
AI: Life Sciences
warum

GSK mRNA-vaccine delivery system — A61K39/39 + A61K9/127. Pure biopharma.

Weitere Navigation
Entscheidungen
Rechtstexte
Analysen

Zu Sammlung hinzufügen

0 Einträge hinzufügen zu:

Anmeldung

Registrieren